(Q48134209)

English

Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations.

scientific article published on 15 June 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. (English)

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

5

object named as

Mathias Jucker

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

author name string

Eva Czirr

1

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

Stefanie Leuchtenberger

2

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

Cornelia Dorner-Ciossek

3

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

Anna Schneider

4

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

Edward H Koo

6

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

Claus U Pietrzik

7

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

Karlheinz Baumann

8

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

Sascha Weggen

9

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

language of work or name

0 references

publication date

15 June 2007

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

Journal of Biological Chemistry

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

282

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

34

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

24504-24513

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Alzheimer disease: progress or profit?

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Strategies for disease modification in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

The gamma-secretase complex: membrane-embedded proteolytic ensemble

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

gamma-secretase as a therapeutic target for treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Selective inhibition of Abeta42 production by NSAID R-enantiomers

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

The role of A beta 42 in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Purification and characterization of the human gamma-secretase complex

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Familial Alzheimer disease-linked presenilin 1 variants enhance production of both Abeta 1-40 and Abeta 1-42 peptides that are only partially sensitive to a potent aspartyl protease transition state inhibitor of "gamma-secretase".

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

The biological and pathological function of the presenilin-1 Deltaexon 9 mutation is independent of its defect to undergo proteolytic processing

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Amyloidogenic function of the Alzheimer's disease-associated presenilin 1 in the absence of endoproteolysis

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Proteolytic processing of presenilin-1 (PS-1) is not associated with Alzheimer's disease with or without PS-1 mutations

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

A novel Polish presenilin-1 mutation (P117L) is associated with familial Alzheimer's disease and leads to death as early as the age of 28 years.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Intra- or intercomplex binding to the gamma-secretase enzyme. A model to differentiate inhibitor classes

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

The initial substrate-binding site of gamma-secretase is located on presenilin near the active site

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

The mechanism of gamma-secretase: multiple inhibitor binding sites for transition state analogs and small molecule inhibitors

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

The GxGD motif of presenilin contributes to catalytic function and substrate identification of gamma-secretase.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Signal peptide peptidase: biochemical properties and modulation by nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Presenilin Proteins Undergo Heterogeneous Endoproteolysis between Thr291and Ala299and Occur as Stable N- and C-Terminal Fragments in Normal and Alzheimer Brain Tissue

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

C-terminal Fragment of Presenilin Is the Molecular Target of a Dipeptidic γ-Secretase-specific Inhibitor DAPT (N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycinet-Butyl Ester)

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M700618200

21 January 2018

Identifiers

10.1074/JBC.M700618200

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17573346

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48134209&oldid=1106055722"